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A Conserved Interaction between the SDI Domain of Bre2
and the Dpy-30 Domain of Sdc1 Is Required for Histone
Methylation and Gene Expression*□
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Paul F. South1, Ian M. Fingerman, Douglas P. Mersman, Hai-Ning Du, and Scott D. Briggs2
From the Department of Biochemistry and Purdue University Center for Cancer Research, Purdue University,
West Lafayette, Indiana 47907
In Saccharomyces cerevisiae, lysine 4 on histone H3 (H3K4) is
methylated by the Set1 complex (Set1C or COMPASS). Besides
the catalytic Set1 subunit, several proteins that form the Set1C
(Swd1, Swd2, Swd3, Spp1, Bre2, and Sdc1) are also needed to
mediate proper H3K4 methylation. Until this study, it has been
unclear how individual Set1C members interact and how this
interaction may impact histone methylation and gene expression. In this study, Bre2 and Sdc1 are shown to directly interact,
and it is shown that the association of this heteromeric complex
is needed for proper H3K4 methylation and gene expression to
occur. Interestingly, mutational and biochemical analysis identified the C terminus of Bre2 as a critical protein-protein interaction domain that binds to the Dpy-30 domain of Sdc1. Using
the human homologs of Bre2 and Sdc1, ASH2L and DPY-30,
respectively, we demonstrate that the C terminus of ASH2L also
interacts with the Dpy-30 domain of DPY-30, suggesting that
this protein-protein interaction is maintained from yeast to
humans. Because of the functionally conserved nature of the C
terminus of Bre2 and ASH2L, this region was named the SDI
(Sdc1 Dpy-30 interaction) domain. Finally, we show that the
SDI-Dpy-30 domain interaction is physiologically important for
the function of Set1 in vivo, because specific disruption of this
interaction prevents Bre2 and Sdc1 association with Set1,
resulting in H3K4 methylation defects and decreases in gene
expression. Overall, these and other mechanistic studies on how
H3K4 methyltransferase complexes function will likely provide
insights into how human MLL and SET1-like complexes or overexpression of ASH2L leads to oncogenesis.

In Saccharomyces cerevisiae, histone H3 lysine 4 (H3K4)3
mono-, di-, and trimethylation is mediated by the Set1 histone
methyltransferase (1, 2). Set1 and H3K4 methylation were first
identified to be required for silencing at rDNA, telomeres, and
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mating-type loci (3– 6). Set1 and H3K4 trimethylation are also
found to be located at euchromatin and enriched in the 5⬘-ends
of coding regions of transcriptionally active genes (7, 8). In
addition, Set1 and its human homologs, MLL1, MLL2, and
hSET1, associate with the phosphorylated C-terminal domain
of RNA polymerase II (7, 9 –11). More recently, it has been
shown that various chromodomain and PHD zinc finger-containing proteins can bind to histones and H3K4 di- and trimethylated histone peptides and histones (12–14). Therefore,
these and other studies suggest that Set1-mediated histone
methylation plays a positive role in mediating gene expression
through recruitment of effector proteins.
Unlike other yeast histone methyltransferases, Set1 requires a
multiprotein complex for its activity in vitro and in vivo (1, 15–18).
The yeast Set1 complex, also called Set1C or COMPASS
(complex associated with Set1), consists of eight subunits
(Set1, Bre2, Sdc1, Swd1, Swd2, Swd3, Spp1, and Shg1) (15, 18,
19). After the discovery of yeast Set1C, it was determined that
the human H3K4 methyltransferases MLL1 through 4 and
human SET1 (SET1A and SET1B) form yeast Set1-like complexes (2, 9, 20 –26). The human MLL and SET1 complexes
share most of their core subunits, and these are homologous to
the subunits found in the yeast Set1 complex. The core subunits
consist of ASH2/ASH2L (Bre2), DPY30 (Sdc1), RBBP5 (Swd1),
WDR82 (Swd2), WDR5 (Swd3), and CFP1/CGBP (Spp1) (9,
24 –27). To date, WDR82 has only been identified in the human
SET1 complexes and not in the MLL complexes (2, 11, 23, 24,
28). In yeast, deletion of the individual Set1-associated genes
BRE2, SDC1, SWD1, SWD3, and SPP1 disrupts, to varying
degrees, the levels of H3K4 mono-, di-, or trimethylation in cells
(15–17, 29). In addition, disruption of the human MLL and
SET1 complex members WDR5, RBBP5, and ASH2L leads to
decreases in H3K4 trimethylation, whereas embryonic stem
cells lacking CFP1/CGBP exhibit an increase in H3K4 trimethylation (20, 21, 30, 31). These results suggest that the conserved
Set1C subunits in addition to the SET domain catalytic subunit
are essential for maintaining proper H3K4 methylation.
Several of the yeast and human complex members have been
shown to interact with each other. In yeast lacking Set1, the
only two heteromeric Set1C subunit interactions that remain
intact are a Swd1-Swd3 heteromer and a Bre2-Sdc1 heteromer
(18, 32). Bre2 and Sdc1 have also been shown to interact via
bacterial two-hybrid analysis, and a Bre2-Sdc1 heteromeric
association is needed for them to interact with Set1 (18, 32).
Interestingly, deletion of either of the Set1C heteromer sub-
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units displays similar defects in H3K4 methylation (15–17, 29).
Deletion of SWD1 or SWD3 leads to global loss of H3K4 mono-,
di-, and trimethylation similar to a SET1 deletion, whereas deletion of BRE2 or SDC1 results in global loss of H3K4 trimethylation and reductions in mono- and dimethylation (15–17, 29).
However, how individual yeast or human Set1 complex members interact with each other mechanistically and how their
interaction may impact histone methylation and gene expression has not been thoroughly investigated.
In this study, we focus on defining the interaction of Bre2 and
Sdc1 and how this interaction impacts histone methylation and
gene expression. We demonstrate that Bre2 and Sdc1 can
directly interact with each other without additional yeast proteins. In addition, we identify that the C termini of Bre2 and
ASH2L are required to bind to the Dpy-30 domain of Sdc1 and
DPY-30, respectively. Because this domain appears to be functionally conserved from yeast to humans, we named this new
domain the SDI (Sdc1 Dpy-30 interaction) domain. More
importantly, disrupting the interaction between the SDI and
Dpy-30 domains prevents Bre2 and Sdc1 association with Set1
and results in defective histone H3K4 methylation and gene
expression. These results show the fundamental importance of
this new and conserved protein-protein interaction domain.

EXPERIMENTAL PROCEDURES
Plasmids and Strains—All yeast strains and plasmids used in
this study are described in the supplemental material (see supplemental Tables S1 and S2). Bacterial and yeast plasmids for
full-length BRE2 and SDC1 were made by PCR amplification of
yeast genomic DNA. PCR-amplified BRE2 was subcloned into
a modified pET28b vector (pET28b-9) and a pGEX-KG vector
to generate pPFS25 and pPFS52. SDC1 was subcloned into a
pGEX-2T and pET28b-9 vector to generate pPFS15 and
pPFS40, respectively. Constructs of BRE2 and SDC1 for in vivo
methylation studies were engineered with a 5⬘-hemagglutinin
(HA) sequence and subcloned into the yeast expression vector
pRS415 containing an ADH1 promoter (pRS415/ADH1p) to
make pPFS1 and pPFS2, respectively. Bre2 and Sdc1 constructs
for co-immunoprecipitation studies were engineered with an
N-terminal HA tag or FLAG tag by PCR and subcloned into a
yeast expression vector under the control of the ADH1 promoter
with a URA3- or LEU2-selectable marker to make pPFS45,
pPFS46, or pPFS43. Plasmid constructs, pPFS44 and pPFS47, were
generated by site-directed mutagenesis using pPFS43 as a template. ASH2L was subcloned into the pET28b-9 vector to generate
pPFS36, and DPY-30 was subcloned into the pGEX2T vector to
generate pPFS40. Full-length human ASH2L and DPY-30 were
PCR-amplified from a human cDNA library. All bre2, ash2l, sdc1,
and dpy-30 deletions and point mutations were generated either
by PCR amplification or by using the Stratagene QuikChange sitedirected mutagenesis method using BRE2-, ASH2L-, SDC1-, and
DPY-30-containing plasmids as templates.
In Vitro Binding Analysis—GST, GST-Sdc1, His6-Bre2, and
His6-Sdc1 constructs were bacterially expressed as described
previously (33, 34). GST pull-down assays were done as
described previously (33, 34). Briefly, GST and GST fusion proteins were bound to glutathione-agarose beads and washed
with Buffer A (300 mM NaCl, 50 mM Tris-HCl pH 8.0, 1 mM
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phenylmethylsufonyl fluoride, and 1 g/ml leupeptin, aprotinin, and pepstatin A). After washing, 4 g of immobilized GST
fusion proteins were incubated with 400 l of bacterial whole
cell extract containing His6-tagged proteins. GST fusion protein binding reactions were performed in Buffer A and incubated for 1 h at 4 °C with rotation. After 1 h, the beads were then
washed three times in 1 ml of Buffer A and then resuspended
and boiled in 10 l of 5⫻ SDS sample buffer with 10% ␤-mercaptoethanol. All 10 l of each sample was loaded per lane on a
12% SDS-polyacrylamide gel, transferred to PVDF membrane,
and immunoblotted using an ␣-His antibody (catalog number
sc-8036, Santa Cruz Biotechnology, Inc. (Santa Cruz, CA)).
After immunoblot analysis, the PVDF membrane was stained
with Coomassie Blue stain to visualize GST and GST fusion
proteins. GST pull-down assays using recombinant GSTDPY-30 and His6-ASH2L were performed as described above
with the following modification. 2 g of GST-DPY-30 bound to
glutathione-agarose beads and 150 l of bacteria whole cell
extract containing His6-ASH2L or ASH2L mutants were used
in the binding reaction.
Sdc1 Dimerization and Binding Assays—Bacteria whole cell
extract containing His6-Sdc1 or His6-Sdc1 C47A was prepared
as described above. His6-Sdc1 or His6-Sdc1 C47A was purified
using nickel-agarose beads (Ni2⫹-NTA-agarose, Qiagen) from
whole cell extracts according to the manufacturer’s protocol.
2⫻ SDS sample buffer with or without ␤-mercaptoethanol was
added to Ni2⫹-NTA-agarose beads containing His6-Sdc1 or
His6-Sdc1 C47A. The eluted purified samples were analyzed by
SDS-PAGE and transferred to a PVDF membrane for immunoblot analysis using ␣-His antibody (catalog number sc-8036,
Santa Cruz Biotechnology, Inc.) or stained with Coomassie
Blue. Nickel-agarose binding assays were performed similarly
to the GST fusion binding assays. His6-Sdc1 or His6-Sdc1 C47A
was immobilized on Ni2⫹-NTA beads (Qiagen) and washed
with buffer A (300 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1 mM
phenylmethylsufonyl fluoride, and 1 g/ml leupeptin, aprotinin, and pepstatin A). Bacteria whole cell extract containing
GST-Bre2 was incubated with the Ni2⫹-NTA beads for 1 h at
4 °C with rotation. After three washes in buffer A, pelleted samples were boiled in 10 l of 5⫻ SDS sample buffer with 10%
␤-mercaptoethanol and run on 12% SDS-polyacrylamide gels.
For detection of His6- and GST-tagged Sdc1 and Bre2, SDSpolyacrylamide gels were transferred to PVDF and immunoblotted with ␣-His antibody (catalog number sc-8036, Santa
Cruz Biotechnology, Inc.) or ␣-GST antibody (catalog number
sc-138, Santa Cruz Biotechnology, Inc.).
Yeast Extraction and Immunoblot Analysis—Yeast extraction and immunoblot analysis to detect modified histones were
performed as previously described (5). ␣-H3K4me1 (catalog
number 07-436), ␣-H3K4me2 (catalog number 07-030), and
␣-H3K4me3 (catalog number 07-473) were obtained from Millipore and were used at 1:2500, 1:5000, and 1:5000 dilutions,
respectively. The H3 (catalog number Ab1791, Abcam)-specific antibody at a 1:5000 dilution was used as a loading control.
HA.11 (catalog number MMS-101R, Covance) and 12CA5 (catalog number 1666606, Roche Applied Science) antibodies were
used at a 1:5000 dilution to detect HA-tagged Bre2 and Sdc1,
respectively.
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Co-immunoprecipitation Analysis—For co-immunoprecipitation of HA-Bre2 and FLAG-Sdc1, 50-ml yeast cultures were
grown in select media to mid-log phase. Yeast whole cell
extracts were prepared by bead beating in 400 l of lysis buffer
(40 mM HEPES-NaOH, pH 7.5; 350 mM NaCl; 0.1% Tween 20;
10% glycerol; 1 g of leupeptin, aprotinin, and pepstatin A; 1
mM phenylmethylsulfonyl fluoride), and protein levels were
normalized using a Bradford assay as described previously (35).
To each sample, 10 l of M2 ␣-FLAG resin (catalog number
A2220; Sigma) was added to normalized extracts and incubated
for 3 h at 4 °C with rotation. The immunoprecipitated samples
were washed three times in 1 ml of lysis buffer. The remaining
beads from the final wash were resuspended in 2⫻ SDS sample
buffer with 10% ␤-mercaptoethanol and boiled. Each immunoprecipitated sample was split in half, and 5 l of sample was loaded per
lane on a 12% SDS-polyacrylamide gel, transferred to PVDF membrane, and immunoblotted using ␣-HA polyclonal antibody (catalog number sc-805, Santa Cruz Biotechnology, Inc.) or ␣-FLAG
polyclonal antibody (catalog number F7425, Sigma). Yeast cell
extracts for loading inputs were detected using ␣-HA (HA.11, catalog number MMS-101R, Covance) and ␣-FLAG (catalog number
F7425; Sigma) antibodies.
For immunoprecipitation of Myc3-Set1, the above procedure was performed with the following modifications. To
each sample, 2 g of ␣-Myc antibody (9E10, catalog number
11667203001, Roche Applied Science) was added to normalized extracts and incubated at 4 °C for 2 h. After 2 h, 12 l of
Protein G-Sepharose (catalog number 17-0618-01, GE Healthcare) was added to each sample and incubated for 1 h at 4 °C.
The immunoprecipitated samples were washed three times
with 1 ml of lysis buffer, and the remaining beads were resuspended in 10 l of 2⫻ SDS sample buffer with 10% ␤-mercaptoethanol and boiled. Samples were analyzed on an 8% SDSpolyacrylamide gel, transferred to a PVDF membrane, and
immunoblotted with ␣-Myc antibody (9E10, catalog number
11 667 203 001, Roche Applied Science). For co-immunoprecipitation of HA-Bre2 and FLAG-Sdc1 by Myc3-Set1, Myc3Set1 was immunoprecipitated, as described, and analyzed on a
12% SDS-polyacrylamide gel, transferred to PVDF membrane,
and immunoblotted using ␣-HA polyclonal antibody (catalog
number sc-805, Santa Cruz Biotechnology, Inc.) or ␣-FLAG
polyclonal antibody (catalog number F7425, Sigma).
Gene Expression Analysis—Quantitative real-time PCRs
were performed as previously described (35). Briefly, 6-ml cultures of yeast cells were grown to mid-log phase in selective
media. Total RNA was extracted using the RNeasy kit (Qiagen)
following the manufacturer’s protocol, and 1 g of RNA was
reverse transcribed into cDNA using the Quantitec reverse
transcription kit (Qiagen) according to the manufacturer’s protocol. The real-time PCR mix consisted of 6.25 l of SYBR
green master mix (Applied Biosystems), 0.125 l of each forward and reverse primer from a 5 M stock, 0.5 l of cDNA, and
5.5 l of sterile water. DNA was amplified in a StepOne realtime PCR system (Applied Biosystems) with the following program: an initial hold of 95 °C for 10 min followed by 40 cycles at
95 °C for 15 s and 60 °C for 1 min. Three biological repeats, each
including three technical repeats, were performed for all samples. Data were analyzed using the ⌬⌬Ct method in which actin
JANUARY 1, 2010 • VOLUME 285 • NUMBER 1

(ACT1) was used as the endogenous control, and relative quantity of MDH2 and GUA1 transcript was determined for each
deletion strain compared with MDH2 and GUA1 transcript in a
wild-type strain. Primer sequences used for PCR amplification
are described in supplemental Table S3.
Chromatin Immunoprecipitation Analysis—Chromatin immunoprecipitation (ChIP) was performed as previously
described (33, 35). Briefly, 100-ml cultures were grown to midlog phase in selective media overnight and split in half. Cells
were harvested and cross-linked with 1% formaldehyde. ChIP
was performed using either H3K4 di- or trimethyl-specific antibodies (catalog numbers 07-030 and 07-473, Millipore) or an
antibody specific to H3 (catalog number Ab1791, Abcam) and
Protein G-Sepharose (GE Healthcare). Immunoprecipitated
DNA was amplified by standard PCR methods using primer
sets to analyze the 5⬘- and 3⬘-regions of the MDH2 and GUA1
open reading frames. Amplified PCR products were analyzed
by agarose gel and ethidium bromide staining. Primers used in
ChIP analysis are described in supplemental Table S4.

RESULTS
The Dpy-30 Domain of Sdc1 Is Required for Interaction with
Bre2—In yeast lacking Set1, the Set1 complex is no longer
intact, and only two heteromeric subunit associations remain.
These include an association between Bre2 and Sdc1 and an
association between Swd1 and Swd3 (18). More recently, Bre2
and Sdc1 have also been suggested to interact by bacterial twohybrid analysis (32). Together, these studies indicate that the
Bre2 and Sdc1 subunits directly interact. Until now, how Bre2
and Sdc1 or Swd1 and Swd3 interact has not been established.
In this study, we focus on Bre2 and Sdc1 interaction and the
functional significance of this interaction on histone methylation and gene expression.
To investigate if Bre2 and Sdc1 directly interact, in vitro GST
fusion binding assays were performed in which Escherichia coli
extracts expressing recombinant His6-Bre2 were incubated
with purified GST-Sdc1 fusion protein, GST, or glutathioneagarose beads. We observed that GST-Sdc1 could pull down
His6-Bre2, indicating direct interaction (Fig. 1B, lane 3). This
binding was specific to a Bre2 and Sdc1 protein-protein interaction because Bre2 was not detected when incubated with glutathione-agarose- or GST-containing beads (Fig. 1B, lanes 1
and 2). To determine the region of interaction, mutational analysis and GST fusion binding assays were used to determine
which regions in Sdc1 were important for interacting with Bre2
(Fig. 1A). We initially hypothesized that the SPRY domain of
Bre2 would be important for this interaction. The SPRY
domain was first identified in the tyrosine kinase spore lysis A
(SplA) and in the mammalian ryanodine receptor (RyR) from
which it was named (36). Because SPRY domain-containing
proteins have recently been shown to interact with proteins
containing asparagine-rich sequences, we looked at the primary sequence of Sdc1 for asparagine residues (37, 38). Upon
sequence analysis of Sdc1, we identified an N-terminal asparagine-rich region from amino acids 51– 60 containing six
asparagines. In addition, the Dpy-30 domain of Sdc1, which is a
domain that was initially found in DPY-30 proteins required for
sex determination and dosage compensation in Caenorhabditis
JOURNAL OF BIOLOGICAL CHEMISTRY
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supplemental Fig. S1A). These residues are located in the first predicted ␣-helix of the Dpy-30 domain of Sdc1. Interestingly, based
on the x-ray crystal structure of the
human Dpy-30 domain of DPY-30,
it has been suggested that these
two conserved leucine residues are
probably forming a putative binding
pocket (45). Similar to deletions
within the predicted ␣-helix, all
Sdc1 Leu-134 and Leu-135 mutations (Sdc1 L134E,L135E, Sdc1
L134A,L135A, and Sdc1 L134I,
L135I) disrupted binding to Bre2,
suggesting that the Dpy-30 domain
of Sdc1 might be sufficient to mediate binding to Bre2 (Fig. 1B, lanes
16 –18). In addition, another highly
conserved region found in the
Dpy-30 domain of Sdc1 is a PXXP
motif, which is likely to form a turn
and link the two predicted ␣-helices. Similar to deleting the conserved leucine residues, a PXXP
deletion (Sdc1 ⌬146 –149) is also
FIGURE 1. The Dpy-30 domain of Sdc1 is required for interaction with Bre2 in vitro. A, schematic represen- unable to bind to Bre2 (Fig. 1, A and
tation of Sdc1 and Sdc1 mutants used. The position of the Dpy-30 domain is indicated. B, GST fusion binding
assays were performed to determine the region within Sdc1 responsible for binding Bre2. Purified GST-Sdc1 or B, lane 11). Furthermore, Sdc1
GST-Sdc1 mutants were used to pull down bacterially expressed His6-Bre2 from whole cell extracts. GST and point mutations (Sdc1 P146A and
glutathione-agarose beads (Agarose) were used as controls for nonspecific binding. Input and bound fractions P149A) converting the PXXP motif
of His6-Bre2 were detected by immunoblotting using an ␣-His monoclonal antibody. Immunoblots were
to an AXXA motif also completely
stained with Coomassie Blue to indicate the amount of GST, GST-Sdc1, and GST-Sdc1 mutant proteins used.
disrupt binding of Bre2 to Sdc1,
elegans, has also been predicted to be a protein-protein inter- indicating that the PXXP motif is another important conserved
action domain (39, 40). Dpy-30 domains are similar to RIIa region of the Dpy-30 domain (Fig. 1, A and B, lane 12). Because
domains found in cAMP protein kinase A regulatory subunits mutations in conserved amino acids in the predicted turn
that are known to dimerize (41– 43). Therefore, the Dpy-30 region and ␣-helix region of the Dpy-30 domain of Sdc1 disdomain of Sdc1 could be facilitating dimerization or interac- rupted binding to Bre2, we wanted to determine if the Dpy-30
tions with Bre2. To determine if the Sdc1 asparagine-rich domain in itself was sufficient in binding to Bre2 in vitro. Two
sequence or the Dpy-30 domain was responsible for binding to sizes for the yeast Dpy-30 domain have been reported based on
Bre2, GST-Sdc1 deletion constructs were generated lacking sequence alignments with conserved residues, with one being
these regions (Sdc1 ⌬51– 60 and Sdc1 1–120) (Fig. 1A). To our 41 amino acids in size by Pfam and the other 50 amino acids
surprise, GST-Sdc1 ⌬51– 60 lacking the asparagine-rich se- long published by Dong et al. (46) (supplemental Fig. S1A).
quence was still able to bind Bre2, similar to when full-length Therefore, a GST-Sdc1 fusion construct representing the
Sdc1 is used (Fig. 1B, compare lanes 3 and 4). However, GST- Dpy-30 domain of Sdc1 and the remaining C terminus of Sdc1
Sdc1 1–120 lacking the Dpy-30 domain was unable to bind to (Sdc1 121–175) was generated and used in a GST binding assay
Bre2, suggesting that the Dpy-30 domain is required for Bre2 (Fig. 1A). Our results indicated that the Dpy-30 domain of Sdc1
interaction (Fig. 1B, lane 5).
is sufficient to bind full-length Bre2 (Fig. 1B, lane 22).
Modeling of the yeast Dpy-30 domain suggests that it forms a
Previous bacterial two-hybrid results suggest that Sdc1
structure with an ␣-helix followed by a turn and then another might dimerize (32). In addition, the DPY-30 crystal structure
␣-helix (44). Interestingly, GST fusion binding assays using was solved as a dimer, and RIIa domains have also been shown
Sdc1 deletions (Sdc1 ⌬131–140 and Sdc1 ⌬156 –165) showed to dimerize; therefore, we sought to determine if bacterially
that disrupting either predicted ␣-helix abolishes binding to expressed Sdc1 can dimerize in vitro (41, 43, 45). Interestingly,
Bre2 (Fig. 1, A and B, lanes 9 and 10). Because the deletions Sdc1 dimers were detected on non-reducing polyacrylamide
within the predicted ␣-helices of the Dpy-30 domain abolished gels and disrupted in the presence of the sulfhydryl-reducing
binding to Bre2, we wanted to mutate conserved residues agent ␤-mercaptoethanol, suggesting that a cysteine residue is
located in one of the predicted ␣-helices. Based on sequence mediating this event (Fig. 2, A and B). Because only one cysteine
alignment between various organisms, we identified two highly is present in Sdc1, we mutated it to an alanine (Sdc1 C47A); as
conserved leucine residues, Leu-134 and Leu-135 (Fig. 1A and expected, this point mutation disrupted dimerization when run
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truncation and deletion mutants
(Fig. 3A). Again, GST-Sdc1 was able
to associate with full-length Bre2
but not with GST or glutathioneagarose (Fig. 3B, panel 1). However,
a Bre2 C-terminal truncation
mutant (Bre2 1–124) lacking the
SPRY domain and the C terminus
was unable to bind to Sdc1 (Fig. 3B,
panel 2). In addition, a Bre2 truncation mutant (Bre2 114 –505) lacking
the N terminus of Bre2 but retaining
the SPRY domain and C terminus of
Bre2 was able to bind to Sdc1 (Fig.
3B, panel 3). These results suggest
the possibility that the SPRY domain or the C terminus of Bre2 is
the domain necessary for binding
Sdc1.
To determine if the SPRY domain
of Bre2 was responsible for binding
FIGURE 2. Sdc1 forms a dimer by a disulfide interaction. A, immunoblot analysis of purified His6-Sdc1 and to Sdc1, a Bre2 deletion mutant
His6-Sdc1 C47A in the presence and absence of the reducing agent ␤-mercaptoethanol (␤-ME). B, Coomassie (Bre2 ⌬130 –393) lacking the SPRY
Blue stain of purified His6-Sdc1 and His6-Sdc1 C47A in the presence and absence of the reducing agent ␤-mercaptoethanol. Bands representing Sdc1 monomer and dimer are labeled accordingly. C, nickel-agarose bind- domain and a Bre2 truncation
ing assays were performed to determine if Sdc1 dimerization affected interaction with Bre2. Purified His6-Sdc1 mutant (Bre2 114 – 404) lacking the
and His6-Sdc1 C47A were used to pull down bacterially expressed GST-Bre2 from whole cell extracts. Ni2⫹-NTA- N and C terminus but containing
agarose beads were used as a control for nonspecific binding. Input and bound fraction of GST-Bre2, His6-Sdc1,
and His6-Sdc1 C47A were detected by immunoblotting with ␣-GST or ␣-His monoclonal antibodies. D, GST the SPRY domain and 10 residues of
fusion binding assays were performed to determine if the GST-Sdc1 C47A mutation affected binding of His6- surrounding flanking sequences
Bre2. Purified GST-Sdc1 or GST-Sdc1 C47A was used to pull down bacterially expressed His6-Bre2 from whole
cell extracts. Glutathione-agarose- or GST-bound beads were used as a control for nonspecific binding. Input were generated and tested for interand bound fractions of His6-Bre2, GST, GST-Sdc1, and GST-Sdc1 C47A were detected by immunoblotting with action with Sdc1 (Fig. 3A). Surpris␣-His monoclonal antibodies and Coomassie Blue staining of the immunoblot.
ingly, Sdc1 could still bind the Bre2
deletion mutant lacking the SPRY
on non-reducing gels (Fig. 2, A and B). To determine if Sdc1 domain (Bre2 ⌬130 –393) but was not able to bind the Bre2 Ndisulfide-mediated dimerization was important for binding to and C-terminal truncation mutant containing an intact SPRY
Bre2, a GST-Bre2 fusion protein was incubated with a His6- domain (Bre2 114 – 404) (Fig. 3B, compare panels 4 and 5).
Sdc1 C47A point mutation (Fig. 2C). In addition, GST-Sdc1 These results clearly indicated that that the SPRY domain is not
and GST-Sdc1 C47A were incubated with His6-Bre2 (Fig. 2D). necessary for interaction with Sdc1 and suggest that an
In both cases, the Sdc1 C47A point mutation, which failed to unknown domain in the C terminus of Bre2 is needed for the
dimerize in vitro, was still capable of binding Bre2, suggesting Bre2 and Sdc1 interaction.
To confirm that the C terminus of Bre2 is the region to which
that disulfide-mediated dimerization does not facilitate interaction between Sdc1 and Bre2 (Fig. 2, C and D). We were also Sdc1 binds, a Bre2 truncation mutant lacking the C terminus
unable to detect Sdc1 cysteine-mediated dimers when isolated (Bre2 1– 404) and a Bre2 mutant lacking the N terminus (Bre2
from yeast (data not shown), suggesting that cysteine-mediated 394 –505) were generated and tested for binding to Sdc1 (Fig.
dimerization of Sdc1 is probably an artifact of bacterial expres- 3A). Again, a Bre2 truncation mutant lacking its C terminus
sion. Altogether, our results show that Bre2 and Sdc1 can (Bre2 1– 404) was unable to bind Sdc1, whereas the Bre2
directly interact in vitro and indicate that the Dpy-30 domain of mutant lacking the N terminus (Bre2 394 –505) could still bind
Sdc1 is functionally necessary and sufficient for interaction Sdc1 (Fig. 3B, panels 6 and 7). This suggests that the C terminus
of Bre2 is important for Sdc1 interaction. To further define the
with Bre2.
The C Terminus of Bre2 Is Required for Binding Sdc1—Be- C-terminal region in Bre2 responsible for binding Sdc1, three
cause we determined that the Dpy-30 domain was necessary for Bre2 deletion constructs (Bre2 ⌬410 – 421, Bre2 ⌬445– 474,
Sdc1 interaction with Bre2, we wanted to determine the region and Bre2 ⌬475–500) were generated (Fig. 3A). Although the
of Bre2 important for interacting with Sdc1. The only known Bre2 deletion mutant (Bre2 ⌬410 – 421) could bind to Sdc1,
putative protein-protein interaction domain found within Bre2 similar to wild-type Bre2, Bre2 ⌬445– 474 had a significant
is the SPRY domain (15, 18). Therefore, we predicted that the defect in its ability to bind Sdc1 (Fig. 3B, panels 8 and 9). Howconserved SPRY domain of Bre2 would be the site of Sdc1 bind- ever, Sdc1 binding was completely abolished when using the
ing. Utilizing the GST fusion binding assay, GST-Sdc1, GST, Bre2 ⌬475–500 deletion mutant, indicating that these amino
and glutathione-agarose beads were incubated with extracts acids of Bre2 are key determinants for interacting with Sdc1
expressing either full-length His6-Bre2 or various His6-Bre2 (Fig. 3B, panel 10).
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Previous work has suggested that
the Set1 complex may contain two
copies of Bre2 by a Bre2 dimer (1,
32). To test if Bre2 does interact
with itself, we performed an in vitro
pull-down assay with GST-Bre2 and
His6-Bre2. Our data show that we
can pull down Bre2 with Sdc1, but
we are unable to detect a direct
interaction of Bre2 with itself, suggesting that Bre2 does not dimerize
(Fig. 4D, compare lanes 3 and 4).
This result indicates that if there are
multiple Bre2 subunits in the Set1
complex, they may not be interacting directly with each other as a
dimer. However, additional quantitative experiments will be needed to
determine the accurate stoichiometry of Bre2 within the Set1 complex.
Interaction between Human
ASH2L and DPY-30 Occurs through
FIGURE 3. The C terminus of Bre2 is required for interaction with Sdc1 in vitro. A, schematic representation the C Terminus of ASH2L and the
of Bre2 and Bre2 mutants used. The positions of the SPRY domain and SDI domain are indicated. B, GST fusion Dpy-30 Domain of DPY-30—Conbinding assays were performed to determine the region within Bre2 responsible for binding Sdc1. Purified
sistent with the previous findings
full-length GST-Sdc1 was used to pull down bacterially expressed His6-Bre2 or His6-Bre2 mutants (shown in
panels 1–10) from whole cell extracts. GST and glutathione-agarose beads (Agarose) were used as controls for for the Bre2 and Sdc1 interaction,
nonspecific binding. Input and bound fractions of His6-Bre2 were detected by immunoblotting using anti-His the human homolog of Bre2,
monoclonal antibody. Immunoblots were stained with Coomassie Blue to indicate the amount of GST and
ASH2L, has been shown to interact
GST-Sdc1 proteins used.
with the human homolog of Sdc1,
DPY-30 (23). Similar to Bre2 and
Because the Bre2 ⌬445– 474 deletion mutant almost abol- Sdc1, the regions important for how ASH2L and DPY-30 interishes binding to Sdc1, we wanted to further define the region of act have not been established. In addition, no protein-protein
Bre2 needed for binding Sdc1. Therefore, two smaller Bre2 interaction domains that mediate the interaction between
C-terminal deletions were generated (Bre2 ⌬445– 464 and Bre2 ASH2L and DPY-30 have been identified. Although ASH2L has
⌬464 – 474) and tested for their ability to bind Sdc1 (Fig. 4A). a conserved SPRY domain, it is distinct from Bre2 because it
Interestingly, both Bre2 deletions (Bre2 ⌬445– 464 and Bre2 also contains a PHD zinc finger (Figs. 3A and 5A). DPY-30 and
⌬464 – 474) were capable of binding to Sdc1 similar to full- Sdc1 appear to be more similar because they both contain a
length Bre2 (Fig. 4B, compare panels 1–3). Therefore, the Bre2 Dpy-30 domain, with each being 41 amino acids in size as
⌬445– 474 deletion mutant that nearly abolishes interaction reported by Pfam with a 35.7% identity and 73.8% similarity
with Sdc1 is likely due to the size of the deletion and is probably (Figs. 1A and 5A and supplemental Fig. S1A) (44). GST fusion
disrupting the ability of the C-terminal residues 475–505 of binding assays were performed to determine direct interaction
Bre2 to interact with Sdc1.
between ASH2L and DPY-30. GST-DPY-30, GST, and glutathiOur data show that C-terminal residues 475–500 of Bre2 are one-agarose beads were incubated with extracts expressing
necessary for interaction with Sdc1 (Fig. 3B, panel 10). How- full-length His6-ASH2L (Fig. 5B, lanes 1–3). Our results show
ever, to determine if this region is sufficient for interacting with that ASH2L and DPY-30 can directly interact without the addiSdc1, two Bre2 truncation mutants (Bre2 445–505 and Bre2 tion of other MLL- and SET1-associated protein factors. Simi475–505) were generated and tested for binding to Sdc1 (Fig. lar to Sdc1, deletion of the highly conserved PXXP (Dpy-30
4A). Our results show that Bre2 445–505 and Bre2 475–505 can ⌬77– 80) motif within the Dpy-30 domain of DPY-30 disrupted
bind Sdc1 similar to full-length Bre2 (Fig. 4C, compare lanes binding of ASH2L (Fig. 5B, lane 4). Because the two highly
3–5). Therefore, the C-terminal region of Bre2 encompassing conserved leucine residues Leu-134 and Leu-135 of the Dpy-30
amino acid residues 475–505 is not only necessary but also domain of Sdc1 are needed for interacting with Bre2, we wanted
sufficient for interaction with the Dpy-30 domain of Sdc1. In to determine if the same conserved leucine residues Leu-65 and
summary, our in vitro results demonstrate that the C terminus Leu-66 found within the Dpy-30 domain of DPY-30 are needed
of Bre2 and the Dpy-30 domain of Sdc1 are both necessary and for interacting with ASH2L. Similar to the Sdc1 leucine mutasufficient for binding to Sdc1 and Bre2, respectively. Further- tions, a DPY-30 mutant (DPY-30 L65E,L66E) was unable to
more, we have defined a novel protein-protein interaction interact with ASH2L (Fig. 5B, lane 8). These results show the
domain in Bre2 that probably consists of amino acids 475–505, first functional importance of the conserved PXXP motif and
leucine residues in Sdc1 and DPY-30.
which we have designated the SDI domain.
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whole cell extracts (18, 19). Therefore, we wanted to determine if the
interaction between Bre2 and Sdc1
that occurs in vivo was also mediated by the SDI and Dpy-30 domain
interaction that occurs in vitro.
To determine this, we generated
yeast expression constructs containing FLAG-Sdc1, FLAG-Sdc1
PXXP deletion mutant (FLAGSdc1 ⌬146 –149), HA-Bre2, or HABre2 truncation mutant (HA-Bre2
1– 404) lacking the SDI domain. All
constructs were expressed from a
CEN plasmid containing a constitutive ADH1 promoter (ADH1p) with
either a LEU2- or URA3-selectable
marker.
To determine if the Dpy-30
domain was responsible for mediating Sdc1 and Bre2 interactions in
vivo, vector (LEU2), FLAG-Sdc1, or
FLAG-Sdc1 PXXP deletion mutant
FIGURE 4. The SDI domain of Bre2 is sufficient for interaction with Sdc1 in vitro. A, schematic representation of
(FLAG-Sdc1 ⌬146 –149) was coexBre2 and Bre2 mutants used. Domains are indicated as in Fig. 3. B, GST fusion binding assays were performed to
pressed
with full-length HA-Bre2
determine regions necessary for interaction with Sdc1. Purified full-length GST-Sdc1 was used to pull down bacterially expressed His6-Bre2 or His6-Bre2 mutants from whole cell extracts. C, GST fusion binding assays were per- or vector (URA3) in a bre2⌬sdc1⌬
formed to determine the Bre2 region sufficient for interacting with Sdc1. Purified full-length GST-Bre2 or GST-Bre2
truncation mutants were used to pull down bacterially expressed His6-Sdc1 from whole cell extracts. D, a GST fusion double deletion strain. Whole cell
binding assay was performed to determine if Bre2 is able to form a homodimer in vitro. Purified full-length GST-Sdc1 yeast extracts were generated, and
or GST-Bre2 was used to pull down bacterially expressed His6-Bre2 from whole cell extracts. Controls for B, C, and D co-IP analysis was preformed from
were similar. GST and glutathione-agarose beads (Agarose) were used as controls for nonspecific binding. Input and
bound fractions were detected by immunoblotting using ␣-His monoclonal antibody. Immunoblots were stained the bre2⌬sdc1⌬ strain expressing
with Coomassie Blue to indicate the amount of GST and GST fusion proteins used.
these constructs. As expected, fulllength HA-Bre2 was able to be coTo determine if the PHD zinc finger was mediating interac- immunoprecipitated with FLAG-Sdc1 (Fig. 6A, lane 5). This
tion with the Dpy-30 domain of DPY-30, the N terminus of co-IP was specific for an Sdc1 and Bre2 interaction because
ASH2L, which contains a PHD zinc finger, was deleted (Ash2l nonspecific interactions were not detected in lanes expressing
156 –534) and tested for binding to DPY-30. The PHD zinc only vectors, HA-Bre2, FLAG-Sdc1, or FLAG-Sdc1 ⌬146 –149
finger deletion mutant could still bind to DPY-30 (Fig. 5B, panel (Fig. 6A, lanes 1– 4, top panel). However, an Sdc1 mutant lack9), suggesting that the PHD zinc finger has other functions in ing its PXXP motif (FLAG-Sdc1 ⌬146 –149) was unable to assothe MLL and SET H3K4 methyltransferase complexes. Because ciate with HA-Bre2 in vivo, although equivalent amounts of
the C terminus of Bre2 containing amino acids 475–500 and the full-length Sdc1 and Sdc1 PXXP deletion mutant were immulast 26 amino acids of ASH2L are 25.9% identical and are 46.2% noprecipitated (Fig. 6A, compare lanes 5 and 6, top two panels).
similar, we wanted to determine if the SDI domain in Bre2 was These results are consistent with and support our in vitro GST
functionally conserved in ASH2L (supplemental Fig. S1B) (44). fusion binding assays (Fig. 1). The inability of the Sdc1 PXXP
Consistent with our previous results with Bre2, binding of deletion mutant (FLAG-Sdc1 ⌬146 –149) to co-immunopreASH2L with full-length DPY-30 was abolished only when the C cipitate Bre2 was not due to varying expression levels of Sdc1,
terminus of ASH2L (Ash2L 303–508 and Ash2L 1–508) was Sdc1 ⌬146 –149 mutant, or Bre2 because nearly equivalent levmissing (Fig. 5B, panels 10 and 11). These results suggest that els were detected (Fig. 6A, lanes 2– 6, bottom two panels).
To determine if the SDI domain was also needed for in vivo
the C terminus of ASH2L likely represents the SDI domain that
we defined in the C terminus of Bre2. Altogether, our study interaction between Bre2 and Sdc1, vector (LEU2) or FLAGdefines, for the first time, the domains of interaction between Sdc1 was coexpressed with vector (URA3), full-length HAthe yeast and human Bre2/ASH2L and Sdc1/DPY-30 subunits. Bre2, or HA-Bre2 C-terminal truncation mutant (HA-Bre2
Furthermore, we define the SDI domain as a novel protein- 1– 404) lacking the SDI domain in a bre2⌬sdc1⌬ double deleprotein interaction domain that interacts with the Dpy-30 tion strain. Similar to Fig. 6A, co-immunoprecipitation analysis
domain and show that this interaction is functionally conserved determined that full-length Sdc1 and Bre2 interact, whereas
FLAG-Sdc1 was unable to co-immunoprecipitate HA-Bre2
in yeast and humans.
The Binding of Bre2 and Sdc1 in Yeast Requires the SDI- 1– 404 lacking the SDI domain although equal amounts of Sdc1
Dpy30 Domain Interaction—It has previously been reported was immunoprecipitated (Fig. 6B, compare lanes 5 and 6, top
that Bre2 and Sdc1 will co-immunoprecipitate from yeast two panel). In addition, the co-IP was specific for an Sdc1 and
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results are consistent with and support our in vitro binding assays
(Figs. 3 and 4). The inability of Sdc1
to co-immunoprecipitate with the
Bre2 mutant (Bre2 1– 404) lacking
the SDI domain was not due to varying expression levels of Sdc1, Bre2,
or Bre2 1– 404 because nearly
equivalent levels were detected (Fig.
6B, lanes 2– 6, bottom two panels).
Altogether, our results show that
the SDI-Dpy-30 protein-protein
domain interaction is critical for
Bre2 and Sdc1 interaction to occur
in vitro and in vivo. In addition, our
data would suggest that this interaction is probably important for in
vivo histone H3K4 methylation.
Interaction between the Bre2
SDI and Sdc1 Dpy-30 Domains
Is Required for Global H3K4
Methylation—Although we have
defined how Sdc1 and Bre2 interact,
we wanted to determine if the interaction between the SDI and Dpy-30
FIGURE 5. ASH2L and DPY-30 interact through their SDI and Dpy-30 domains. A, schematic representation of domain was physiologically relevant
ASH2L and DPY-30 and corresponding mutants used. Positions of annotated domains are depicted. B, GST fusion
binding assays were performed to determine critical regions for ASH2L and DPY-30 interaction. Purified full-length for global H3K4 methylation. To
GST-DPY-30, GST-Dpy-30 ⌬77– 80, or GST-Dpy-30 L65E,L66E was used to pull down bacterially expressed His6- determine if the Dpy-30 domain of
ASH2L or His6-Ash2L mutants from whole cell extracts. GST and glutathione-agarose beads (Agarose) were used as
controls for nonspecific binding. Input and bound fractions of His6-ASH2L and His6-Ash2L mutants were detected Sdc1 was necessary for proper
by immunoblotting using anti-His monoclonal antibody. Immunoblots were stained with Coomassie Blue to indi- H3K4 methylation, HA-Sdc1 fullcate the amount of GST, GST-DPY-30, GST-Dpy-30 ⌬77– 80, and GST-Dpy-30 L65E,L66E proteins used.
length (Sdc1 1–175), HA-Sdc1 deletion mutant (Sdc1 ⌬51– 60) lacking
the asparagine-rich region, HA-Sdc1 C-terminal truncation
mutant (Sdc1 1–120) lacking the entire Dpy-30 domain, HASdc1 mutants (Sdc1 ⌬131–140, Sdc1 ⌬156 –165, Sdc1 ⌬146 –
149, and Sdc1 P146A,P149A) with deletions or point mutations
in the Dpy-30 domain, and a HA-Sdc1 (Sdc1 C47A) point
mutation were generated and expressed in the sdc1⌬ strain.
Immunoblot analysis of whole cell extracts using H3K4 mono-,
di-, and trimethyl-specific antibodies were used to determine if
the various Sdc1 constructs could rescue the H3K4 methylation
defects in an sdc1⌬ strain. As expected, full-length Sdc1
restored the H3K4 methylation in an sdc1⌬ strain to a level
similar to what is seen in wild-type (WT) cells (Fig. 7, compare
lanes 1 and 3, top three panels). Interestingly, an Sdc1 deletion
mutant (Sdc1 1–120) lacking the Dpy-30 domain and the ability
to bind Bre2 in vitro and in vivo was unable to rescue H3K4
methylation and had H3K4 methylation levels similar to an
sdc1⌬ strain (Fig. 7, lanes 2 and 5). In addition, all mutations
within the Dpy-30 domain of Sdc1 (Sdc1 ⌬131–140, Sdc1
FIGURE 6. The SDI and Dpy-30 domains are required for Bre2 and Sdc1
⌬156 –165, Sdc1 ⌬146 –149, and Sdc1 P146A,P149A) that fail
protein-protein interaction in vivo. A and B, whole cell extracts expressing
vector or the indicated Sdc1 or Bre2 constructs in bre2⌬sdc1⌬ strains were to interact with Bre2 also fail to rescue H3K4 methylation in
immunoprecipitated (IP) with M2 ␣-FLAG resin. Detection of FLAG-Sdc1, sdc1⌬ cells (Fig. 7, lanes 6, 7, 12, and 13). However, all of the
FLAG-Sdc1 mutants, HA-Bre2, or HA-Bre2 mutants were determined by
Sdc1 mutants that were still able to interact with Bre2, such as
immunoblotting with ␣-FLAG or ␣-HA antibodies.
the Sdc1 ⌬51– 60 lacking the asparagine-rich sequence or the
Bre2 interaction because nonspecific interactions were not Sdc1 C47A point mutation, were fully capable of rescuing
detected in lanes expressing vectors, HA-Bre2, FLAG-Sdc1, or H3K4 methylation (Fig. 7, lanes 4 and 11). These differences in
HA-Bre2 1– 404 (Fig. 6B, lanes 1– 4, top panel). Again, these H3K4 methylation patterns did not appear to be due to differ-
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HA-Bre2 mutant (Bre2 1– 404) lacking the C terminus containing the SDI domain, and HA-Bre2 deletion mutant (Bre2
⌬410 – 421, Bre2 ⌬445– 474, and Bre2 ⌬474 –500) constructs
were generated and expressed in a bre2⌬ strain. Immunoblot
analysis of whole cell extracts using H3K4 mono-, di-, and trimethyl-specific antibodies were used to determine if the various Bre2 constructs could rescue the H3K4 methylation defects
in a bre2⌬ strain. As expected, full-length Bre2 could rescue
H3K4 methylation in a bre2⌬ strain similar to wild-type levels
(Fig. 7, compare lanes 14 and 16). Interestingly, all Bre2
mutants (Bre 1– 404, Bre2 ⌬445– 474, and Bre2 ⌬474 –500)
that are compromised in their ability to bind Sdc1 were unable
to rescue the H3K4 methylation defects of a bre2⌬ strain (Fig. 7,
compare lanes 15, 17, 19, and 20). In contrast, a Bre2 deletion
mutant (Bre2 ⌬410 – 421) retaining the SDI domain and ability
to bind Sdc1 was able to rescue H3K4 methylation (Fig. 7, lane
18). The differences in ability to rescue H3K4 methylation levels in strains expressing Bre2 or the Bre2 mutants were not due
to varying levels of protein expression or histone H3 levels
because ␣-HA and H3 immunoblots detected nearly equivalent
amounts of Bre2, Bre2 mutants, and histone H3 protein (Fig. 7,
lanes 14 –20, bottom two panels).
Interaction between the Bre2 SDI and Sdc1 Dpy-30 Domains
FIGURE 7. The SDI and Dpy-30 domains are required for proper levels of Is Required for Association with Set1 and Proper H3K4
global histone H3K4 methylation. Yeast whole cell extracts generated Methylation—Prior work has suggested that the Bre2 and Sdc1
from wild-type (WT), sdc1⌬, and bre2⌬ strains expressing vector, Sdc1, or
Bre2 constructs were immunoblotted with histone H3K4 mono-, di-, and heteromer must be formed prior to incorporation into the Set1
trimethyl-specific antibodies. Histone H3 and HA immunoblots were used complex, because deletion of either Bre2 or Sdc1 will prevent
for a loading control or detection of Sdc1 and Bre2 protein levels,
the other protein from interacting with the Set1 complex (18,
respectively.
32). Furthermore, our data show
that disrupting the binding between
the SDI domain of Bre2 and Dpy-30
domain of Sdc1 in vivo leads to
defects in global levels of H3K4
methylation similar to what is seen
in bre2 and sdc1 deletion strains
(Fig. 7). To determine if mutations
in the Dpy-30 domain of Sdc1
and/or deletion of the SDI domain
of Bre2 prevented interaction with
Set1, BRE2 and SDC1 were both
deleted in a yeast strain where Set1
was N-terminally Myc3-tagged at
its endogenous locus (Myc3-Set1).
Vector (LEU2), HA-Bre2, HA-Bre2
⌬475–500, FLAG-Sdc1, and FLAGSdc1 L134I,L135I constructs were
coexpressed with vector (URA3),
HA-Bre2, or FLAG-Sdc1 in the
Myc3-SET1, bre2⌬, sdc1⌬ strain. As
expected, immunoprecipitated Set1
could co-immunoprecipitate fulllength HA-Bre2 and FLAG-Sdc1
when cells were co-expressing wildFIGURE 8. The SDI-Dpy-30 domain interaction is required for the Bre2 and Sdc1 heteromeric complex to
type Bre2 and Sdc1 (Fig. 8A, lane 6).
associate with Set1. A, co-immunoprecipitation analysis from Myc3-SET1, bre2⌬sdc1⌬ strains expressing vector or the indicated Sdc1 or Bre2 constructs. Detection of Myc3-Set1, FLAG-Sdc1, FLAG-Sdc1 mutants, HA-Bre2, The co-IP of Bre2 and Sdc1 by Set1
or HA-Bre2 mutants was determined by immunoblotting with ␣-Myc, ␣-FLAG, or ␣-HA antibodies. is specific because we do not detect
B, whole cell extracts generated from Myc3-SET1, bre2⌬, and sdc1⌬ strains expressing vector or the indicated
Sdc1 or Bre2 constructs were immunoblotted with histone H3K4 mono-, di-, and trimethyl-specific antibodies. nonspecific interactions in lanes exHistone H3 immunoblots were used for a loading control.
pressing only vectors (Fig. 8A, lane 1).
ences in histone H3 loading or expression of Sdc1 or Sdc1
mutants because nearly equivalent levels of histone H3 and
Sdc1 expression were detected (Fig. 7, lanes 1–13, bottom two
panels).
To investigate if the SDI domain of Bre2 was necessary for
proper H3K4 methylation, full-length HA-Bre2 (Bre2 1–505),
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The Bre2 SDI and Sdc1 Dpy-30
Domains Are Required for Genespecific Methylation and Proper
Gene Expression—To verify that
defects in global H3K4 methylation
observed by Bre2 and Sdc1 mutants
lacking the C-terminal SDI domain
or the Dpy-30 domain, respectively,
also occur on genes, ChIP analysis
was performed on the GMP synthetase, GUA1, and malate dehydrogenase, MDH2, open reading
frames using H3K4 di- and trimethyl-specific antibodies. ChIP
inputs and histone H3 antibodies
were used as controls (Fig. 9, A and
B, bottom two panels). Chromatin
immunoprecipitation eluates were
analyzed by standard PCR using
primers designed to analyze the 5⬘and 3⬘-ends of GUA1 and MDH2
(supplemental Table S4). We chose
to examine H3K4 di- and trimethylation levels at GUA1 and MDH2
because in a recently published
FIGURE 9. The SDI and Dpy-30 domains are required for proper gene-specific H3K4 methylation. A and B, microarray analysis, GUA1 and
ChIP analysis from the indicated strains was performed using antibodies specific to H3K4 di- and trimethylation MDH2 were shown to be putative
and histone H3. ChIP eluates were PCR-amplified using primer sets directed to the 5⬘- and 3⬘-ends of the open
reading frames of GUA1 and MDH2 and analyzed by agarose gel electrophoresis and ethidium bromide stain- targets of the E3 ubiquitin ligase
ing. Input and histone H3 were used as loading controls. The depicted ChIP analysis is a representation of three Not4 (47). In addition, it has
biological repeats. WT, wild type.
recently been shown that Set1,
In contrast, Set1 could not co-immunoprecipitate HA-Bre2 or Not4, and Jhd2 can modulate H3K4 methylation levels at GUA1
HA-Bre2 ⌬475–500 in the absence of Sdc1 or co-immunopre- (35). Similar to global histone methylation levels, a loss of H3K4
cipitate FLAG-Sdc1 or FLAG-Sdc1 L134I,L135I in the absence trimethylation and a decrease in dimethylation at the 5⬘- and
of Bre2 (Fig. 8A, lanes 2, 3, 4, and 5). Furthermore, Set1 failed to 3⬘-ends of GUA1 and MDH2 were detected in bre2⌬ and sdc1⌬
co-immunoprecipitate HA-Bre2 ⌬475–500 or FLAG-Sdc1 strains (Fig. 9, A and B, lanes 3, 4, 9, and 10). However, H3K4 triL134I,L135I in the presence of wild-type Sdc1 or Bre2, respec- and dimethylation was restored to wild-type levels when fulltively (Fig. 8A, lanes 7 and 8). The inability of HA-Bre2, FLAG- length BRE2 and SDC1 were ectopically expressed (Fig. 9, A and
Sdc1, HA-Bre2 ⌬475–500, or FLAG-Sdc1 L134I,L135I to co- B, lanes 5, 6, 11, and 12). Importantly, the Bre2 and Sdc1
immunoprecipitate with Set1 was not due to significant change mutants that are defective in binding to each other, Bre2 1– 404
in protein expression levels because nearly equivalent levels lacking the SDI domain or Sdc1 ⌬146 –149 lacking the PXXP
were detected (Fig. 8A, lanes 2– 8, bottom two panels). In addi- motif within the Dpy-30 domain, had gene-specific H3K4 dition, nearly equivalent levels of Set1 were immunoprecipitated and trimethylation defects similar to what is observed in bre2⌬
in all samples (Fig. 8A, lanes 1– 8, top panel). In agreement with and sdc1⌬ strain (Fig. 9, A and B, lanes 7, 8, 13, and 14).
Set1-mediated H3K4 methylation is important for proper
the co-immunoprecipitation data, global H3K4 mono-, di-, and
trimethylation are only restored when Bre2 and Sdc1 can inter- gene expression (3– 6, 8, 35, 48 –50). However, until now, it has
act and associate with Set1 (Fig. 8B, lane 6). In contrast, when not been demonstrated if Bre2 or Sdc1, two Set1-associated
Bre2 and Sdc1 cannot interact and thus cannot associate with factors required for proper H3K4 methylation, are also needed
Set1, global H3K4 methylation remains defective (Fig. 8B, lanes for appropriate levels of expression at constitutively active
2–5, 7, and 8). Taken together, our results show that the SDI- genes. Because our chromatin immunoprecipitation analysis
Dpy-30 interaction is not only critical for mediating a Bre2- determined that a Bre2 and Sdc1 interaction is critical for modSdc1 heteromeric complex but also necessary for Bre2 and Sdc1 ulating H3K4 di- and trimethylation levels at GUA1 and MDH2
to associate with Set1. These results also help explain why dis- open reading frames, we wanted to determine if GUA1 and
rupting the SDI-Dpy-30 interaction leads to defects in global MDH2 expression levels were also being modulated. Using
H3K4 mono-, di-, and trimethylation. Further investigation will quantitative real-time PCR analysis, we examined gene expresbe needed to determine if the SDI and Dpy-30 domains are sion of GUA1 and MDH2. We determined that defects in H3K4
directly or indirectly associating with Set1 or if other regions histone methylation that occur in bre2⌬ and sdc1⌬ strains coinwithin Bre2 and Sdc1 are responsible for direct or indirect con- cided with an about 2-fold decrease in GUA1 expression relative to wild-type cells (Fig. 10, A and B, and supplemental Table
tact with Set1.
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FIGURE 10. The SDI and Dpy-30 domains are required for appropriate
levels of gene expression. A–D, expression of GUA1 or MDH2 was determined in the indicated strains by quantitative real-time PCR analysis. All
expression analysis was relative to wild-type (WT) cells using actin (ACT1) as
an internal control to normalize expression levels. Data in A–D were analyzed
from four biological repeats with three technical repeats each.

S5). This decrease in GUA1 expression was similar to what we
have observed for set1⌬ and not4⌬ strains (35). Furthermore,
GUA1 gene expression levels in bre2⌬ and sdc1⌬ expressing
full-length Bre2 and Sdc1, respectively, were rescued at levels
similar to those of wild type (Fig. 10, A and B, and supplemental
Table S5). More importantly, Bre2 and Sdc1 mutants (Bre2
1– 404, and Sdc1 ⌬146 –149) that were defective in binding and
H3K4 methylation showed a decrease in GUA1 expression levels (Fig. 10, A and B, and supplemental Table S5).
To confirm that these changes in GUA1 transcript levels
were not specific only to the GUA1 locus, the MDH2 locus was
also analyzed. Similar to GUA1, MDH2 transcript levels were
decreased about 3-fold in bre2⌬ and sdc1⌬ strains when compared with wild-type cells (Fig. 10, C and D, and supplemental
Table S5). Furthermore, MDH2 gene expression levels in bre2⌬
and sdc1⌬ expressing full-length Bre2 and Sdc1, respectively,
were rescued to nearly wild-type levels (Fig. 10, C and D, and
supplemental Table S5). More importantly, Bre2 and Sdc1
mutants (Bre2 1– 404 and Sdc1 ⌬146 –149) that were defective
in binding and H3K4 methylation also showed a defect in
MDH2 expression levels (Fig. 10, A and B, and supplemental
Table S5). Altogether, our results show that when interactions
between Bre2 and Sdc1 are disrupted, Bre2 and Sdc1 no longer
associate with each other or Set1; consequently, this leads to
defects in global and gene-specific histone H3K4 methylation
and decreases in gene expression.

DISCUSSION
In this study, we determined for the first time how two Set1associated subunits, Bre2 and Sdc1, form a heteromeric complex. We show that the Dpy-30 domain of Sdc1 is critical for
mediating interactions with Bre2. We identified a new proteinprotein interaction domain located at the C terminus of Bre2,
which we have named the SDI domain because it is needed to
interact with the Dpy-30 domain of Sdc1. More importantly, we
show that the SDI-Dpy-30 domain interaction is required for
formation of the heteromeric Bre2 and Sdc1 complex and assoJANUARY 1, 2010 • VOLUME 285 • NUMBER 1

ciation with Set1. Without this interaction, histone H3K4
methylation and gene expression is disrupted. Finally, we determine that the human homologs of Bre2 and Sdc1, ASH2L and
DPY-30, respectively, also associate in a similar manner involving the C terminus of ASH2L and the Dpy-30 domain of DPY30. Our findings would suggest that the SDI-Dpy-30 domain
interaction is a conserved interaction for yeast Set1 and human
MLL and SET1-like complexes. The ASH2L and DPY-30 interaction is also likely to impact histone H3K4 methylation and
gene expression in humans and other organisms.
In this study, we determined that the Dpy-30 domains of
Sdc1 and human DPY-30 are required for interacting with Bre2
and ASH2L, respectively. Because all mutations within the
Dpy-30 domain of Sdc1 disrupted interaction with Bre2, it is
likely that the overall structure of the Dpy-30 domain is important for interacting with the C terminus of Bre2. Interestingly,
during preparation of this manuscript, the x-ray crystal structure of the Dpy-30 domain of human DPY-30 was solved (45).
The structure indicates that the human DPY-30 domain can
form a four-helix bundle. Based on the human crystal structure
and structure prediction analysis of yeast Sdc1, it appears that
deletions of the PXXP motif or mutations that change the prolines to alanines are within a loop region connecting two ␣-helices (45, 51). Therefore, it is likely that this loop is important for
the overall structure or position of the two ␣-helices. In addition, this might explain why Sdc1 deletion mutations within the
predicted helices on either side of the PXXP loop would disrupt
binding to Bre2 (Fig. 1B). From the crystal structure, it was also
predicted that two highly conserved leucine residues, Leu-65
and Leu-66, form a putative binding pocket for interaction with
ASH2L (45). Our data support this idea and show that mutations of the conserved leucines in Sdc1 and DPY-30 disrupt
binding to Bre2 and ASH2L, respectively (Figs. 1B and 5B).
It has been predicted that Dpy-30 dimerization is important
for Sdc1 and Bre2 association with Set1 (1). This idea is based
on bacterial two-hybrid analysis of Sdc1 indicating that the
Dpy-30 domain can dimerize and on the predicted stoichiometry of the individual Set1-associated proteins within the Set1
complex (18, 32). In addition, the recently solved x-ray crystal
structure of the Dpy-30 domain of human DPY-30 also forms a
dimer (45). Although we also show that Sdc1 could form disulfide-mediated dimers from bacterially expressed Sdc1, we were
unable to determine if there is any physiological relevance for
Sdc1 dimerization in yeast. For example, we were unable to
detect disulfide-mediated dimerization of Sdc1 from yeast
(data not shown), and a mutation of Sdc1 (Sdc1 C47A) that
abolished dimerization in vitro had no effect on H3K4 methylation in vivo or binding to Bre2 (Figs. 2, C and D, and 7). More
work will be needed to determine if the disulfide-dependent or
independent dimerization of Sdc1 is physiologically relevant or
an artifact of bacterial expression and/or crystallization conditions. It is also possible that the Sdc1 or DPY-30 dimerization
observed in vitro occurs because a physiologically relevant
binding partner, such as the SDI domain of Bre2 or ASH2L, is
not present. Therefore, future studies with the co-crystal of the
SDI domain of Bre2 or ASH2L with Sdc1 or DPY-30, respectively, would be useful in clarifying the importance of Sdc1 and
DPY-30 dimerization.
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A surprising result from our mutational analysis and binding
studies indicated that the C termini of Bre2 and ASH2L are
important for interacting with Sdc1 and DPY-30, respectively.
This result was quite interesting because the only domain common to both Bre2 and ASH2L that was annotated as a proteinprotein interaction domain is the SPRY domain. The function
of the SPRY domain is currently unknown, but it is likely to be
important for interacting with either Set1, Set1-associated subunits within the yeast and human MLL and SET1 complexes, or
other transcription factors (15, 52). In this study, we have identified a new protein-protein interaction domain within Bre2
and ASH2L that we named the SDI domain. By homology
searching, the SDI domain of Bre2 and ASH2L showed no significant matches to any other known domain. However, secondary structure prediction of the SDI domain of Bre2 and
ASH2L suggests that the C terminus forms an ␣-helix structure
(44). Interestingly, a domain that shares similarity to the
Dyp-30 domain is the RIIa domain. Structural analysis has indicated that the Dpy-30 and RIIa domains can both form fourhelix bundles and can dimerize. RIIa domains are commonly
found within the regulatory subunit of cyclic AMP-dependent
protein kinase A and are required for dimerization (41, 43).
Recently, the structure of the RIIa domain and its binding partner A kinase-anchoring protein has been solved, and it was
determined that an A kinase-anchoring protein ␣-helix was
bound to the RIIa domain (41, 43). Intriguingly, when we compared the C terminus of Bre2 and mouse A kinase-anchoring
protein ␣-helix that binds the RIIa domain, there was a 22.1%
identity (44). Currently, it is unclear if the A kinase-anchoring
protein ␣-helix is functionally similar to the SDI domain or
structurally similar but with specificity toward the RIIa domain.
Because of the functional conservation of the SDI predicted
␣-helical domain from yeast to humans, the SDI domain or
domains of structural similarity may be important for interaction with other Dpy-30 or RIIa domains containing partners.
Based on our data, the crystal structure of the human Dpy-30
domain, and the conserved amino acids within the SDI and
Dpy-30 domains, it is likely that the SDI-Dpy-30 interaction is
mediated by the conserved hydrophobic and/or charged amino
acids (supplemental Fig. S1). However, additional biochemical
and structural studies will be needed to determine the precise
mode of interaction.
In this study, we also show that an interaction between the
SDI domain of Bre2 and the Dpy-30 domain of Sdc1 is functionally important for Bre2 and Sdc1 to form a heteromeric
complex and association with Set1 so that proper histone methylation and gene expression can occur. However, more work
will be needed to establish the regions within Bre2 and Sdc1
required for association with Set1 or other Set1 complex members. Based on our work and recent data suggesting that Bre2,
Sdc1, and ASH2L bind to the SET domain of yeast Set1 or
human MLL1, it is likely that the Bre2 and Sdc1 heteromeric
complex permits interaction with the SET domain of Set1,
allowing for full methyltransferase activity (18, 32, 53–55).
Because we also showed that human ASH2L and DPY-30 interact in a similar manner, we would expect this interaction could
enhance the in vitro catalytic activity of the human MLL- and
SET1-like complex or be required for in vivo trimethylation.
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Although it is still unclear if an SDI-Dpy-30 domain interaction
is required, RNA interference knockdown of either human
ASH2L or C. elegans DPY-30 can lead to defects in H3K4 methylation (20, 30, 56). In addition, it has recently been shown that
recombinant ASH2L and DPY-30 heteromeric dimer and
RbBP5 by itself can stimulate the catalytic activity of recombinant MLL1 by directly binding to the SET domain (53–55).
However, the addition of both heteromeric dimers, ASH2LDPY-30 and Wdr5-RbBP5, to recombinant MLL results in a
further enhancement of catalytic activity (53–55). It has been
proposed that the heteromeric dimers help stabilize the SET
domains of MLL and SET1-like methyltransferases, so the SET
domain is in the right conformation for full methyltransferase
activity (53). Future studies will be required to determine if the
SDI-Dpy-30 domain interaction is required for stabilizing the
SET domain conformation and for H3K4 methylation in other
organisms.
Although bre2⌬ and sdc1⌬ strains have been shown to have
histone methylation defects, the basic observation that disruption of histone methylation in these strains coincides with
defects in gene expression within euchromatin has not been
reported. In this study, we show that loss of BRE2 or SDC1 or
disruption of their SDI-Dpy-30 domain interaction results in
expression defects at constitutively active genes. In addition,
the decrease in gene expression observed at two loci strongly
coincides with H3K4 methylation defects and is also consistent
with microarray analysis of a set1 deletion strain showing a
general 2-fold defect in global gene expression (8, 48, 50).
Because RNA interference knockdown of ASH2L in mammalian cells results in histone methylation and gene expression
defects, we would expect that disruption of the SDI-Dpy-30
interaction would also result in gene expression defects in
human and other organisms (20, 30). Recently, ASH2L has also
been found overexpressed in cancer cells and is thought to
function as an oncoprotein (57). Although the molecular mechanism by which ASH2L mediates oncogenesis is unknown, it
could be due to a consequence of either too little or too much of
an association with DPY-30, resulting in reduced or overactive
MLL or SET1 methyltransferase activity and consequently
leading to aberrant gene expression. Therefore, our study and
others that determine the interaction and function of yeast and
human Set1-associated proteins are important and will probably impact human health and diseases and provide insight into
novel therapeutic targets.
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